

RECORDATI: PUBLIC DISCLOSURE COMPLIANCE

Milan, 10th May 2017 - Recordati announces that the minutes of the Ordinary and Extraordinary Shareholders' Meeting held on 11 April 2017 as well as the corporate Bylaws, as amended by the aforementioned Extraordinary Shareholders' Meeting, are available at the Company's registered office, on the Company's website (www.recordati.com; Section Investors, Shareholders' Meetings) as well as on the "1info" storage mechanism (www.1info.it).

Please be also informed that, pursuant to article 72, paragraph 6, lett. b) of Consob Regulation n. 11971 of 14 May 1999 and subsequent amendments, by way of the same means mentioned above (as for the Company's website - www.recordati.com - in the Section Corporate Governance, Other Corporate Documents), the minutes of the Board of Directors meeting held on 4th May 2017 are available.

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,100, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in the main European countries, in Russia, in other Central and Eastern European countries, in Turkey, in North Africa, in the United States of America, in Mexico and in some South American countries. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2016 was € 1,153.9 million, operating income was € 327.4 million and net income was € 237.4 million.

For further information:

Recordati website: www.recordati.com

Investor Relations

Marianne Tatschke
(39)0248787393
e-mail: inver@recordati.it

Media Relations

Studio Noris Morano
(39)0276004736, (39)0276004745
e-mail: norismorano@studionorismorano.com

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Sede Legale
VIA M. CIVITALI, 1
20148 MILANO, ITALIA
TEL. (39) 0248787.1
FAX (39) 0240073747

CAPITALE SOCIALE € 26.140.644,50 I.V.
REG. IMP. MILANO N. 00748210150
CODICE FISCALE/P.IVA 007482210150
R.E.A. MILANO N. 401832